S&P 500   4,567.80
DOW   35,950.89
QQQ   388.83
The top-rated strong-buy stocks on Marketbeat’s radar
The Only Practical Solution to the World’s Looming Energy Crisis (Ad)
Marketbeat’s AI-powered tools for investors
Are blue chip stocks a good investment?
The Only Practical Solution to the World’s Looming Energy Crisis (Ad)
As Dollar Tree Goes, So Goes the Consumer?
Power Play: GE's game-changing technology for EVs and grids
The Only Practical Solution to the World’s Looming Energy Crisis (Ad)
Is Beyond an overlooked e-commerce winner?
Inflation in Europe falls to 2.4% as interest rates pack a punch. But the economy has stalled
S&P 500   4,567.80
DOW   35,950.89
QQQ   388.83
The top-rated strong-buy stocks on Marketbeat’s radar
The Only Practical Solution to the World’s Looming Energy Crisis (Ad)
Marketbeat’s AI-powered tools for investors
Are blue chip stocks a good investment?
The Only Practical Solution to the World’s Looming Energy Crisis (Ad)
As Dollar Tree Goes, So Goes the Consumer?
Power Play: GE's game-changing technology for EVs and grids
The Only Practical Solution to the World’s Looming Energy Crisis (Ad)
Is Beyond an overlooked e-commerce winner?
Inflation in Europe falls to 2.4% as interest rates pack a punch. But the economy has stalled
S&P 500   4,567.80
DOW   35,950.89
QQQ   388.83
The top-rated strong-buy stocks on Marketbeat’s radar
The Only Practical Solution to the World’s Looming Energy Crisis (Ad)
Marketbeat’s AI-powered tools for investors
Are blue chip stocks a good investment?
The Only Practical Solution to the World’s Looming Energy Crisis (Ad)
As Dollar Tree Goes, So Goes the Consumer?
Power Play: GE's game-changing technology for EVs and grids
The Only Practical Solution to the World’s Looming Energy Crisis (Ad)
Is Beyond an overlooked e-commerce winner?
Inflation in Europe falls to 2.4% as interest rates pack a punch. But the economy has stalled
S&P 500   4,567.80
DOW   35,950.89
QQQ   388.83
The top-rated strong-buy stocks on Marketbeat’s radar
The Only Practical Solution to the World’s Looming Energy Crisis (Ad)
Marketbeat’s AI-powered tools for investors
Are blue chip stocks a good investment?
The Only Practical Solution to the World’s Looming Energy Crisis (Ad)
As Dollar Tree Goes, So Goes the Consumer?
Power Play: GE's game-changing technology for EVs and grids
The Only Practical Solution to the World’s Looming Energy Crisis (Ad)
Is Beyond an overlooked e-commerce winner?
Inflation in Europe falls to 2.4% as interest rates pack a punch. But the economy has stalled

BioSyent (RX) Earnings Date, Estimates & Call Transcripts

C$8.50
-0.10 (-1.16%)
(As of 11/30/2023 05:24 PM ET)
Compare
Today's Range
C$8.49
▼
C$8.50
50-Day Range
C$7.75
▼
C$8.60
52-Week Range
C$6.51
▼
C$8.65
Volume
6,600 shs
Average Volume
4,076 shs
Market Capitalization
C$100.47 million
P/E Ratio
16.67
Dividend Yield
1.88%
Price Target
N/A
Stock AnalysisAnalyst ForecastsChartEarningsHeadlinesInsider Trades
Skip Charts & View Estimated and Actual Earnings Data
Earnings Per ShareRevenue

RX Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

RX Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

BioSyent Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20231C$0.13C$0.13C$0.13
Q2 20231C$0.12C$0.12C$0.12
Q3 20231C$0.10C$0.10C$0.10
Q4 20231C$0.10C$0.10C$0.10
FY 20234C$0.45C$0.45C$0.45

RX Earnings Date and Information

BioSyent has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, March 19th, 2024 based off prior year's report dates.

BioSyent Earnings History by Quarter

Export to Excel
DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
3/19/2024
Estimated)		------- 
8/22/2023Q2 2023C$0.12C$0.12-C$0.12C$7.70 millionC$7.96 million
5/26/2023Q1 2023C$0.13C$0.10C($0.03)C$0.10C$7.60 millionC$6.48 million
3/21/2023Q4 2022-C$0.09+C$0.09C$0.09C$6.90 millionC$7.46 million
11/16/2022Q3 2022C$0.13C$0.12C($0.01)C$0.12C$7.00 millionC$6.79 million
8/23/2022Q2 2022C$0.14C$0.10C($0.04)C$0.10C$7.50 millionC$6.64 million
5/18/2022Q1 2022C$0.11C$0.13+C$0.02C$0.13C$7.00 millionC$7.04 million
3/9/2022Q4 2021C$0.11C$0.15+C$0.04C$0.15C$6.90 millionC$7.22 million
11/18/2021Q3 2021C$0.10C$0.13+C$0.03C$0.13C$6.90 millionC$6.69 million
8/25/2021Q2 2021C$0.10C$0.08C($0.02)C$0.08C$5.90 millionC$7.29 million
5/27/2021Q1 2021C$0.09C$0.13+C$0.04C$0.13C$6.10 millionC$7.42 million
3/17/2021Q4 2020C$0.07C$0.05C($0.02)C$0.05C$5.50 millionC$5.73 million












BioSyent Earnings - Frequently Asked Questions

When is BioSyent's earnings date?

BioSyent has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, March 19th, 2024 based off last year's report dates. Learn more on RX's earnings history.

How much revenue does BioSyent generate each year?

BioSyent (CVE:RX) has a recorded annual revenue of C$30.78 million.

How much profit does BioSyent generate each year?

BioSyent (CVE:RX) has a recorded net income of C$6.21 million. RX has generated C$0.51 earnings per share over the last four quarters.

What is BioSyent's price-to-earnings ratio?

BioSyent (CVE:RX) has a trailing price-to-earnings ratio of 16.67 and a forward price-to-earnings ratio of 16.33.


More Earnings Resources from MarketBeat

Related Companies:
Earnings Tools:
Earnings By Country:
Latest Articles:
This page (CVE:RX) was last updated on 12/1/2023 by MarketBeat.com Staff

My Account -